41263-94-9
41263-94-9 structure
- Name: 2'-Fucosyllactose
- Chemical Name: 2′-Fucosyl-D-lactose
- CAS Number: 41263-94-9
- Molecular Formula: C18H32O15
- Molecular Weight: 488.43800
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2017-01-08 14:00:44
- Modify Date: 2026-07-02 07:39:31
-
2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines[1][2].
| Name | 2′-Fucosyl-D-lactose |
|---|---|
| Synonyms |
2-FUCOSYL-D-LACTOSE
2'-Fucosyllactose - Synthetic Deoxy-5-propgyloxyuridine Terthiophene-5-cboxaldehyde Nitrophenyl-b-D-xylopyranoside &ge Deoxy-2-fluoroadenosine H)-yl)methyl)-4-fluorobenzonitrile biphenyl]-4-yl]methyl]-cyclopentanecboxamide Deoxy-2-O-ethyluridine 13C5]Uridine Methoxybiphenyl-4-boronic acid pinacol ester Deoxy-6-thio Guanosine 2'-FUCOSYLLACTOSE FROM HUMAN MILK diphosphate trisodium salt hydrate Methyl-adenosine-(Bz)-succinyl-G ALPHA-L-FUC-[1-]-BETA-D-GAL-[1-]-D-GLC 5R)-4-[(2S (2R,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal O-monothiophosphate 6R)-4 Isopropylacetanilide Deoxy-5-azacytidine (HPLC) alpha-L-Fu-(1-)-beta-D-Galp-(1-)-D-GlNAc fluoroinosine α-l-fuc-(1→2)-β-d-gal-(1→4)-d-glc FUC-ALPHA1-2GAL-BETAGLC 2'FL-BSA Deoxy-5-iodouridine O-6-deoxy-alpha-L-galactopyranosyl-O-beta-D-galactopyranosyl- (2R i docetaxel N-[[5-(Dimethylamino)-1-naphthalenyl]sulfonyl]-L-&gamma Methoxy-biphenyl-4-cbaldehyde D]imidazole, Hydrochloride Hydrate (Glu-P-1) O-DMT-guanosine-(DMF)-succinyl G 1000Å 2'-Fucosyllactose - min D-abinofuranosyluracil Deoxy-N-(2-methyl-1-oxopropyl)-guanosine Fluoro-5-methyl-1-&beta Hydroxy-3-phenylpropiophenone 41-9 2-Fucosyllactose 2'FL AC1L55O8 HMDB02098 D-Glucose O-DMT-N4-isobutyrylcytidine 5-dihydroxy-6-(hydroxymethyl)-3-[(2S difluorocytidine C-Methylinosine 2'Fucosyllactose (2'FL) (Fmoc-aminomethyl)biphenyl-2-cboxylic acid (HPLC) Cyanobiphenyl-3-cboxylic acid glutamyl-L-cysteinylglycine Bimol. (2&rr Deoxy-5-iodocytidine (2R,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxy-oxan-2-yl]oxy-2,3,5,6-tetrahydroxy-hexanal Acetoxycocaine Hydrochloride Deoxy-N6-methyladenosine 4-Bis(aminophenyl)methane fluoroadenosine-triphosphate tetralithium salt kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-cboxylicacid,5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-,methyl ester, (9S,10R,12R) [(a,b)-methyleno]triphosphate sodium salt Deoxy-N2-isobutyrylcytidine |
| Description | 2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Target: IFN-γ, IL-6, IL-17, and TNF-α[1] |
| In Vitro | 2'-Fucosyllactose (2'-FL; 0-12 mg/mL; 48 h) suppress cell-associated CD14 expression and to attenuate LPS (100 μg/mL) stimulated IL-8 secretion in T84 cells[1]. 2'-Fucosyllactose (2 mg/mL; 48 h; T84 and HCT8 cells) ameliorates inflammation induced by bacterial invasion. 2'-Fucosyllactose inhibits ETEC invasion and attenuated the consequent IL-8 secretion[1]. 2'-Fucosyllactose (2 mg/mL; 48 h; T84 and HCT8 cells) induces macrophage migration inhibitory factor signal pathways that suppress inflammation[1]. Western Blot Analysis[1] Cell Line: T84 cells Concentration: 0, 2, and 4 mg/mL Incubation Time: 48 hours Result: Suppressed CD14 mRNA and reduced cell-associated CD14 protein expression. Western Blot Analysis[1] Cell Line: T84 and HCT8 cellsT84 and HCT8 cells Concentration: 2 mg/mL Incubation Time: 48 hours Result: Suppressed CD14 mRNA and reduced cell-associated CD14 protein expression. Inhibited CD14 and NF-κB induction. Induced iκB and SOCS2 expression and STAT3 phosphorylation. |
| In Vivo | 2'-Fucosyllactose (2'-FL; 100 mg (200 μL); i.g.; daily, for 4 d; C57BL/6 mice with AIEC infection) inhibits AIEC infection and inflammation in vivo[1]. Animal Model: C57BL/6 mice (8 weeks) with AIEC (uropathogenic E. coli, and adherent-invasive E. coli) infection[1] Dosage: 100 mg (200 μL) Administration: Oral gavage; daily, for 4 days Result: Had colons lengths were closer to normal. Inhibited the colonisation of the colonic mucosa by O83-positive bacteria. Decreased CD14 expression, CD14 mRNA levels, IL-6, IL-17 and TNF-α levels in colonic. |
| References |
| Density | 1.68g/cm3 |
|---|---|
| Boiling Point | 902.2ºC at 760 mmHg |
| Melting Point | 230-231 °C |
| Molecular Formula | C18H32O15 |
| Molecular Weight | 488.43800 |
| Flash Point | 311.9ºC |
| Exact Mass | 488.17400 |
| PSA | 248.45000 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.631 |